Granulomatosis With Polyangiitis Clinical Trial
Official title:
Randomized Trial of Tofacitinib Versus Methotrexate for Maintenance Therapy in Granulomatosis With Polyangiitis
The aim of this study is to identify the optimal maintenance therapy for granulomatosis with polyangiitis (GPA) by comparing the MTX (standard regimen) with Tofacitinib in terms of efficacy, i.e. in preventing relapses.
Granulomatosis with polyangiitis (GPA), a systemic small-vessel vasculitis, could involve multiple tissues and organs. Remission of GPA can be obtained in approximately 80% of the patients with a combination of corticosteroids and cyclophosphamide. However, relapses are frequent and remain a challenge. The optimal drug for maintenance treatment is not determined. Tofacitinib is a Jak inhibitor which has been proved to be effective in multiple inflammatory diseases such as rheumatoid arthritis. But the efficiency and safety of tofacitinib in treating GPA remains unclear yet. In the present randomized trial, the comparison of MTX (standard regimen) with Tofacitinib in terms of efficacy, i.e. in preventing relapses will be conducted. ;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT01731561 -
Comparison Study of Two Rituximab Regimens in the Remission of ANCA Associated Vasculitis
|
Phase 3 | |
Completed |
NCT01862068 -
Neutrophils as Prognostic Factors in Granulomatosis With Polyangiitis (Formerly Named Wegener's Granulomatosis)
|
||
Completed |
NCT01750697 -
A Phase IIa Study of Intravenous Rituximab in Pediatric Participants With Severe Granulomatosis With Polyangiitis (Wegener's) or Microscopic Polyangiitis
|
Phase 2 | |
Not yet recruiting |
NCT02126098 -
Observation Study of Clinical Manifestation and Outcome in Chinese Patients With Pulmonary Vasculitis
|
N/A | |
Terminated |
NCT01586858 -
Rituximab for ANCA-associated Vasculitis (RAVE) Long-Term Follow-Up Study
|
N/A | |
Active, not recruiting |
NCT03919435 -
TEMPO Study: Trimethoprim-Sulfamethoxazole in Granulomatosis With Polyangiitis
|
Phase 1/Phase 2 | |
Not yet recruiting |
NCT04871191 -
Study of Salvage Therapy to Treat Patients With Granulomatosis With Polyangiitis
|
Phase 2 | |
Terminated |
NCT05376319 -
PR3-AAV Resilient Remission or PRRR
|
Phase 2 | |
Not yet recruiting |
NCT05353179 -
Study on Pharmacokinetics of Meperizumab Injection and NUCALA® in Healthy Male Volunteers
|
Early Phase 1 | |
Completed |
NCT02169219 -
Pilot Study of Short-Course Glucocorticoids and Rituximab for Treatment of ANCA-Associated Vasculitis
|
Phase 4 | |
Completed |
NCT01613599 -
An Observational Study of The Safety of MabThera/Rituxan (Rituximab) in Participants With Granulomatosis With Polyangiitis (Wegener's) or Microscopic Polyangiitis
|
||
Active, not recruiting |
NCT05716334 -
Biosimilars of Rituximab in ANCA-associated Vasculitis Compared to the Originator
|
||
Completed |
NCT03430388 -
Yellow Fever Vaccine in Patients With Rheumatic Diseases
|
N/A | |
Completed |
NCT03410290 -
Journey of Patients With Vasculitis From First Symptom to Diagnosis
|
||
Recruiting |
NCT03482479 -
Low Dose Naltrexone to Improve Physical Health in Patients With Vasculitis
|
Phase 2 | |
Active, not recruiting |
NCT01940094 -
The Assessment of Prednisone In Remission Trial - Centers of Excellence Approach
|
Phase 3 | |
Recruiting |
NCT01405807 -
Alemtuzumab for ANCA Associated Refractory Vasculitis
|
Phase 4 | |
Active, not recruiting |
NCT01933724 -
The Assessment of Prednisone In Remission Trial (TAPIR) - Patient Centric Approach
|
Phase 3 | |
Completed |
NCT05703802 -
Establishment of an ELISA for the Recognition of Procalcitonin Variants in Patients With Hyperprocalcitonemia.
|
||
Active, not recruiting |
NCT03967925 -
Rituximab and Belimumab Combination Therapy in PR3 Vasculitis
|
Phase 2 |